{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-037624","form_type":"8-K","ticker":"CADL","cik":"0001841387","company_name":"Candel Therapeutics, Inc.","filed_at":"2024-03-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.919778+00:00","generated_at":"2026-06-04T06:32:42.331494+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Candel reports Q4 2023 net loss $11.1M; cash $35.4M; Phase 3 prostate data on track for Q4 2024","bullets":["Net loss Q4 2023 $11.1M vs $5.1M Q4 2022; full year net loss $37.9M vs $18.8M.","Cash and equivalents $35.4M at Dec 31, 2023 ($70.1M end 2022); expects runway into Q4 2024.","R&D expenses $7.3M Q4 2023 ($5.0M Q4 2022) and $24.5M full year ($20.8M 2022).","FDA Fast Track Designations: CAN-2409 for NSCLC and pancreatic cancer, CAN-3110 for recurrent HGG.","Anticipated milestones: Phase 2 NSCLC data Q2 2024; Phase 3 prostate topline data Q4 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-037624","json":"https://secwatch.observer/filing/0000950170-24-037624.json","markdown":"https://secwatch.observer/filing/0000950170-24-037624.md","text":"https://secwatch.observer/filing/0000950170-24-037624.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1841387/000095017024037624/0000950170-24-037624-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1841387/000095017024037624/cadl-20240328.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T06:32:42.331494+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b4632c6b6e29177d3315b4111bf98e0999180b5a","claim":"Candel Therapeutics, Inc. reported the fourth quarter and year ended December 31, 2023 results: net income Net loss for the fourth quarter of 2023 was $11.1 million.","evidence_excerpt":"Candel Therapeutics, Inc. announced its financial results for the quarter and year ended December 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1841387/000095017024037624/0000950170-24-037624-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and year ended December 31, 2023"},{"label":"Net income","value":"Net loss for the fourth quarter of 2023 was $11.1 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}